Member Info for sadoldgit

Good link their Krone.

I should not think any of the deals were made prior to receiving finalised data.

The most important is the safety profile and that was done at 30% of sareums projected 1000mg per day maximum.

I think some here believe that all Tim.has to do is get on the phone, give someone a ring and a shortwhile later a deal is done.

It is not a second hand used car market.

Just available at the pandemic. Early stage of.

Similar profile to baricitinib.

Until the full data is known and finalised, how on earth do you expect a worthwhile deal of any sort?

Until full data is known and finalised we have risk.

We have reached therapeutic levels in the dosing with no reported serious adverse events.

Just what do you expect the BoD to do at this time?

Tim been to Boston.

How can anyone rule out informal licence negotiations and if so the reasons why?

Sareum cannot and will not RNS any detail regarding this.

Regards.

Warty look on the brightside. Emma Walmsley get more in wages than that in one year.

Analyst 4 strong buy,4 buy, 2 hold, forecast 179p share price.

The Sp rises in the morning and then is hammered but the non identified buy sell in black.

How is Sareums SDC not comparable with Deucravacitinib?

Was it over priced in the deal?

Why did it fail in Ulcerative Colitus?

How much was paid for it?

How good was the phase 2b Pasi score?

Why are other companies creating inhibitors that they believe can out perform?

Why would SDC1802 not prove significantly better efficacy as dual inhibition over allosteric Tyk2 and the factual scientific rationale supporting this?

Why do the fools on ADVN choose to copy and paste garbage from here over on ADVN?

They know who they are.

If you think you are that clever, wolf of wolf Street sonny boy, then copy and paste this over on ADVN.

Regards

You are out of your league to answer the questions but you can at least copy and paste sonny.

Below from 2022 the deal to which our SDC1801 is in the same arena?

Under the terms of the agreement, Takeda will pay Nimbus Therapeutics $4 billion upfront, and sales-based milestone payments up to $2 billion. The transaction is expected to be finalized in the first half of 2023. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. Nimbus Therapeutics will retain ownership of its other research and development subsidiaries. Takeda will be solely responsible for future development and commercialization of NDI-034858 and other TYK2 inhibitors.

Regards

Something a bit different

https://fintel.io/sfo/gb/sar#:~:text=The%20average%20one%2Dyear%20price,a%20high%20of%20184.80%20GBX.

Phase 2b not cost a great deal.

People here stating 10 million needed. What is that based on and by who?

I do remember a very likeable poster that began with P and ended in A.

As far as l can remember it were that constant posting of 10 million was established.

However a phase 2a trial in Psoriasis with a couple of dozen patients over a 6 month period with a cost of circa 50 k per patient equates to around a million for that alone.

That leave around 1 to 2 million for set up fees and general company associated costs wages Edison and professional advice CRO cost.

Thst would indicate proof of concept.

Phase 2b considerably higher and typically requires a 100 to 200 patient enrolment.

The longer the trial the greater the cost of course.

Apart from the hypothesis of Tyk2 and Jak one having dual inhibition along with the results of in vitro and in vivo preclinical studies there is nothing 100% guarantee success. This can only be achieved via finalised trial data.

However, the most important aspect at this time is its safety which will be confirmed on receipt of finalisation of trial results.

Sareum.expectation in Q3. That should be more than a sufficient amount of time to complete.

Of course this finalised data is main constituent of the data package.

Just as preclinical results were used as data package for CTA so a data package from phase1 to phase 2a will be required.

I suggest Sareum use a CTO company to assist in this and hence achieve a smooth transition.

This is my opinion nothing else. It ain't financial advice.

It is neither a ramp or a deramp.

All I am saying is that Sareum will have a choice now of options, not so limited as that of the RF catastrophe.

Regards.

We now get back to the data again.

Finalised data is required.

Until such data has been obtained there is very little chance of either

On licence.

Company takeover or buyout.

This however does not mean that a non dilutive alternative to raise funds cannot be achieved.

Very little cash burn up at the moment.

Regards

Good morning Wayne.

I have been looking deeply into the Bio meeting in June 2024.

There are many companies that attend and much is done in the way of partnerships.

There is a list in the link below but this is by no means exhaustive.

It is understandable as to why TM would go.

Some here would consider it a jolly for Tim.

Interesting to note us the amount of funding these companies have received. Many if them are Chinese companies.

'https://www.drugdiscoverytrends.com/100-best-funded-biotech-companies-2015-to-present/

Some of these companies are more than capable of progressing mid to late stage clinical trial in both auto immune and oncology.

Indeed there are some smaller companies as thus is only the top 100 listed

Take a look at your leisure.

Regards

Wes

Cobaltblue, you clearly are frustrated as indicated by the nature of your postings undermining posters of their lack of grammatical and spelling ability. You have nothing to offer in the terms of reasonable debate.

Cobalt do you suggest l sell up my entire holding on Monday?

I am fairly certain that would cause a significant further drop. The snowball gathering pace and size cascading down a mountain until an avalanche evolves.

Surfie.

Surfie it is called market sentiment.

A rise was on the cards on positive RNS.

We had a ramper in Lsesar. Stating a 100% rise on positive news.

Now correct me if l am wrong!

He then claims to have sold and then postulates doom and gloom down to the 20's

The talk now on the board is going down to 20p.

Tell me if what l have stated is wrong and if so your reasons as to why.

Market sentiment. Tell me what drives it.

People glean information from this chat board correct?

I will add here that the 1802 successful phase 2 data results to the compound.

If we own it which l doubt as will have been sold by then it is worth 2 billion.

I stated SDC1802 value not Sareum value

Regards

It's called character assassination.

It states that l am a Nuclear Scientist.

Am l Lsesar?

It should go out and try a game of golf l think to unwind. Not sure if it can however.

It a achieves it's objectives by creating discontent.

I say a value of 2 billion pounds for SDC1802 on good phase2 data.

How much did Takeda end up paying Nimbus Therapeutics for their compound?

Initially offered 800 million but eventually paid 4 billion upfront with l billion in milestone.

As for addressing our financial situation l and others are very aware. On good news a tendency to rise followed by a retrace.

A rise of around 50% plus was my prediction, First thing on the morning it briefly hit 52p.

Now some have sold. I don't blame them for taking a profit.

What l do object to, is the continual focus then in creating negative sentiment amongst posters.

They tell lies and or state incorrect facts.

They have an agenda as sold at a peak after their prediction of a 100% rise and on the day sell a vast amount of what they held.

There have been a vast amount of shares created by dilution. By placing a glut of shares on the market will reduce the price.

In previous times when there was a drop the SP recovered somewhat.

We are now seeing a trading pattern

Soon as the share goes up in the morning it is knocked back in the afternoon.

It will discourage people from buying.

Deliberate creation of one sided negativity that attacks and constantly attempts to undermine any positive poster, that includes when they post and also if they have not posted.

Regards

Good afternoon AndytheMKDon.

I will add that although the finalised trial results will take a while as is a complex issue we will be going through a period of low cash burn up.

Below is a link to Clinical trial report finalisation which will be concluded.

https://www.ncbi.nlm.nih.gov/books/NBK286004/

Why would not the first Tyk2 Jak1 inhibitor with good results in phase2 not be worth 2 billion?

Explain yourself Lsesar.

I have previously posted overtones of your post

lubleyjubley.

This hangs around GSK as l an concerned.

The individual that scuppered this theory was workingonpharma. News on developments of 737 can't say much nudge nedge wink wink

Someone has paid a pittance up front again.

No developments but question we must ask is why?

6 months now and getting a tad peeved with no news.

The biggy we have of course is 1802.

Definitely to be feared amongst the new snd upcoming inhibitors.

Tim and Co know what they have. The scientists but I feel lacking in marketing abilities.

The other outcome of course is informal discussions are resulting in offers that Sareum not interested in.

Should 2802 progress in safety and potential benefits of 1801 the market is far higher.

With a novel inhibitor such as 1802 it l would hazard a guess be with close to 2 billion plus on decent phase 2 data. Of course subject to Indications and take into consideration patented now fit use in immune.

It may well be far bigger than what we think.

Thoth gave overtones of 1802 of 2 billion a few years back. Whilst I did not agree with everything he said, in someway he was quite astute.

It is a new novel compound similar but not exact of 1801

Similarity is formed of similar molecules to 1801 albeit different selectivity.

For those that choose to want to mock Sareum.

Sareum CCT245737 dis what it was designed to do xnd that was stabilise progression of disease.

Prevent metastases.

Although disease did progress in some patients and this is partially due to DNA damage Repair pathway the cancer taking an alternative route the dreaded cancer resistance.

Hence potential of on combo therapy.

We are plagued a tad by the doubt of bti g able to raise adequate funding.

Certainly what we have way exceeds the current market cap.

However we suffer from market sentiment.

Interesting should Sareum announce commencement of 1802 in trial.

Speculation!

Have a good evening.

Good evening Lutonnews

Lots of scaremongering and very dubious posters.

Results in Q3 looking like September to one.

Results been pushed a tad. Absolutely no problem as Results so far indicate we can progress to phase 2a.

However, until data arrives and l reckon that will be this month then news should follow with progression.

There will be some side affects and in some studies the side affects have been nigh equal to placebo.

In Deucravacitinib the placebo was more effective if you look in detail than Deucravacitinib.

Large numbers required is nature of game.

If l were Sareum I would fund raise circa 3 million and take it through stage 2a as proof of concept in Psoriasis.

Share price for flat ever reason being suppressed.

Many shares can flood the market and create downward pressure

Large deals on small percentage risings will give a return

Close to 40 million been added since we boarded the titanic RF finance

They are gone but there will be antics played by large recent share a accumulators in groups.

It will settle itself over the next few weeks. But meantime volatility.

We do pose a serious threat to our Competitors and subsequent billions of lost revenue over the life span patented protection of a drug.

Very few on here l would trust probably around 8.

Yes sure we can get peeved when the price drops

But must focus on on licence and the ever impending likelihood of takeover.

Regards and those that attend tommorrow meet all the best.

Surfie what you on about you fool going AWOL, l am working at the moment on a licenced Nucleaer establishment where mobile phones are not allowed on site. In addition the security systems in place prevent access to websites.

Share price was up 15% a couple of minutes past 8. So nothing underhanded with the Mm's.

SP eased back created by influx of selling.

Doom and gloom postings do not help.

These people have an agenda and is not for the benefit of Sareum or its shareholders.

Regards

That is how l understand it Silverfoil 13.

There are advantages in more ways than 1